These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15997651)

  • 21. [Inflammation, oxidative stress and kidney function in arterial hypertension].
    Cerasola G; Guarneri M; Cottone S
    G Ital Nefrol; 2009; 26 Suppl 46():8-13. PubMed ID: 19644813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renovascular hypertension, endothelial function, and oxidative stress.
    Matz R
    N Engl J Med; 2002 Nov; 347(19):1528-30; author reply 1528-30. PubMed ID: 12422892
    [No Abstract]   [Full Text] [Related]  

  • 23. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation.
    Miriyala S; Gongora Nieto MC; Mingone C; Smith D; Dikalov S; Harrison DG; Jo H
    Circulation; 2006 Jun; 113(24):2818-25. PubMed ID: 16769910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of tempol on endothelium-dependent vasodilatation and blood pressure.
    Simonsen U; Christensen FH; Buus NH
    Pharmacol Ther; 2009 May; 122(2):109-24. PubMed ID: 19268689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive hyperemic pre-ejection shear stress of brachial artery determines endothelial function in patients with untreated essential hypertension.
    Lee MY; Chu CS; Lee KT; Wu CM; Sheu SH; Lai WT
    Int J Cardiol; 2007 Oct; 122(1):68-71. PubMed ID: 17188375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular oxidative stress is associated with insulin resistance in hyper-reninemic nonmodulating essential hypertension.
    Sanchez R; Fischer P; Cuniberti L; Masnatta LD; Ramírez AJ
    J Hypertens; 2007 Dec; 25(12):2434-40. PubMed ID: 17984665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of oxidative stress in elevated blood pressure induced by high free fatty acids.
    Wang H; Li H; Hou Z; Pan L; Shen X; Li G
    Hypertens Res; 2009 Feb; 32(2):152-8. PubMed ID: 19262475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
    Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antioxidant therapy effectiveness: an up to date.
    Iannitti T; Palmieri B
    Eur Rev Med Pharmacol Sci; 2009; 13(4):245-78. PubMed ID: 19694341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of exertional hypertension evoked by weight lifting on vascular endothelial function.
    Jurva JW; Phillips SA; Syed AQ; Syed AY; Pitt S; Weaver A; Gutterman DD
    J Am Coll Cardiol; 2006 Aug; 48(3):588-9. PubMed ID: 16875990
    [No Abstract]   [Full Text] [Related]  

  • 31. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction.
    Münzel T; Sinning C; Post F; Warnholtz A; Schulz E
    Ann Med; 2008; 40(3):180-96. PubMed ID: 18382884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endothelial dysfunction in cardiovascular diseases (Data from XIII European Conference on Arterial Hypertension)].
    Ostroumova OD; Dubinskaia RE
    Kardiologiia; 2005; 45(2):59-62. PubMed ID: 15798711
    [No Abstract]   [Full Text] [Related]  

  • 33. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.
    Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M
    Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease.
    Reddy PH
    J Neurochem; 2006 Jan; 96(1):1-13. PubMed ID: 16305625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension.
    Irace C; Cortese C; Fiaschi E; Scavelli F; Liberatoscioli L; Federici G; Gnasso A
    Hypertens Res; 2008 Mar; 31(3):507-13. PubMed ID: 18497471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Obesity and endothelial dysfunction].
    Taddei S; Ghiadoni L; Salvetti G; Virdis A; Salvetti A
    G Ital Cardiol (Rome); 2006 Nov; 7(11):715-23. PubMed ID: 17216913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protecting the endothelium: a new focus for management of chronic kidney disease.
    Diaz-Buxo JA; Woods HF
    Hemodial Int; 2006 Jan; 10(1):42-8. PubMed ID: 16441826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction and impaired L-arginine transport in hypertension and genetically predisposed normotensive subjects.
    Yang Z; Kaye DM
    Trends Cardiovasc Med; 2006 May; 16(4):118-24. PubMed ID: 16713534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.